No Data
Imugene Valuation Points to 129% Upside as Broker Backs Azer-cel Strategy | ASX:IMU, OTC:IUGNF
Precision BioSciences Exits Substantial Shareholder Role in Imugene
Analysts Offer Insights on Healthcare Companies: Imugene (OtherIUGNF) and Neuren Pharmaceuticals Limited (OtherNURPF)
Imugene Price Target Cut 70% to A$0.25/Share by Bell Potter
Imugene Seeks ASX Quotation for 89 Million New Options
Imugene Restructures Convertible Notes and Raises New Capital for Oncology Trials
151364853 : no idea. some hope for this stock?